Saturday, November 10, 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.


from Reuters: Health https://ift.tt/2qJmYzr

No comments: